We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diatron MI and Medicon Hellas Sign Exclusive Supply Agreement

By LabMedica International staff writers
Posted on 14 Oct 2013
Diatron MI Plc (Budapest, Hungary) and Medicon Hellas SA (Gerakas, Greece) signed an exclusive supply agreement for an extensive range of high quality clinical chemistry reagents for use on the Diatron Pictus range of clinical chemistry analyzers in all international markets except the USA.

All reagents will be manufactured by Medicon Hellas, exclusively for Diatron and have been specifically designed with the Diatron analyzers in mind, so the combination of analyzer and reagents allows customers to employ features and benefits that are only normally possible on high cost clinical chemistry systems. More...
The reagent range will initially consist of 60 test parameters (substrates, enzymes, electrolytes, and specific proteins), which have been developed to meet the needs and demands of today’s modern clinical chemistry laboratory to have precision, linearity, sensitivity, on-board stability, and calibration stability.

Diatron will be exhibiting two new, bench top analyzers at Medica, Dusseldorf (November 20–23, 2013). The new version of the established Abacus 3CT hematology analyzer has been enhanced to make it even easier to use. In addition, Diatron will also be previewing a prototype version of the brand new Pictus 500 clinical chemistry analyzer.

“ We are excited by the new collaboration with Medicon as it will allow us to mutually grow our clinical chemistry business with our global distributor partners and to demonstrate to end-users our commitment to provide them with the full package—a cost effective system (analyzer & reagent) with complete support,“ said Ronald Backes, vice president of International Business- Diatron MI Plc.

“Medicon is delighted to enter into this agreement with Diatron, rewarding the time and effort we have put into developing specific reagents and tests for the Pictus analyzers. We are pleased that customers around the world will now be able to benefit from what Greek laboratories have experienced with the analyzer/reagent combination,” commented Sakis Mitropoulos, director, customer services, Medicon Hellas SA.

Related Links:

Diatron MI
Medicon Hellas



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.